Search Beyond News…

Roche’s Lunsumio‑lenalidomide combo shows PFS gain in relapsed/refractory follicular lymphoma

Executive summary: Roche reported that the phase III CELESTIMO study of Lunsumio plus lenalidomide versus rituximab plus lenalidomide achieved a statistically significant improvement in progression‑free survival in relapsed or refractory follicular lymphoma. The outcome could lead to a new approved regimen for follicular lymphoma, expanding Roche’s oncology portfolio and potentially capturing market share in a relapsed/refractory setting.

Who is involved: Roche, the CELESTIMO study investigators, and patients with relapsed or refractory follicular lymphoma.

Likely next: Roche will likely submit the data to regulatory agencies for label expansion and prepare for possible launch discussions.

Roche announced that its phase III CELESTIMO trial met the primary endpoint, demonstrating that Lunsumio (mosunetuzumab) plus lenalidomide significantly improved progression‑free survival compared with rituximab plus lenalidomide in patients with relapsed or refractory follicular lymphoma. The result positions the bispecific antibody combination as a potential new therapeutic option in a heavily pre‑treated patient population. If confirmed in further analysis, the data could support regulatory submissions and influence treatment algorithms for follicular lymphoma.

What's next — scenarios

Regulatory Acceleration (50%)

Roche gains early approval in the EU/US within 12 months, allowing immediate launch and market share capture in the advanced FL segment.

Label Expansion Delay (30%)

Approval is restricted to specific subgroups or later lines of therapy, reducing the initial revenue potential and forcing longer time-to-market.

Competitive Erosion (20%)

Competing bispecifics (e.g., epcoritamab, glofitamab) secure faster approvals or stronger real-world data, limiting Lunsumio's market uptake.

What to watch

Timeline

Key entities

Sources

Browse the full archive →